The Adams Diversified Equity Fund provides an investor with a pretty plain S&P 500 Index-like exposure in a CEF wrapper. The fund completed a tender offer earlier this year that we were able to take advantage of; they further announced a change in their distribution policy. ADX's new distribution policy provides for a minimum 8% annual payout, smoothing distributions throughout the year, but we could still see a large year-end.
Income investors often favor value investments like midstream infrastructure, equity REITs, and blue-chip cash cows for yields between 5% to 8%. Long-term alpha-like returns are unlikely with these assets, but they offer stable income streams that are suitable for defensive retirement portfolios. Some investors might, however, want to combine high yield with growth-like exposure.
Using diversified funds to gain wide exposure and strong income can be a winning income strategy. One of our picks gives exposure to REITs which are primed to strongly benefit from rate cuts. The other pick has over half a century of strong returns and NAV appreciation.
In the trading world, having the right tools and knowing how to use them correctly can be the difference between success and failure. One such tool is the Average Directional Index (ADX), which is acknowledged as a fundamental indicator for assessing the strength and direction of market trends.
The Adams Diversified Equity Fund has been operating since 1929, offering consistent distributions with a current yield of 6.28%. ADX has historically delivered returns in line with or exceeding the S&P 500, generating slight alpha over the broader market. The investment case for ADX centers on accessing S&P 500-like risks and returns, with primary returns driven by distributions rather than price appreciation.
The broader equity market saw declines in early August but ended near all-time highs to finish off the month. I put some capital to work this month at the low, but not as much as I had planned initially, as the market swiftly recovered. Most of the moves this month were corporate action-driven events, primarily the BlackRock tender offers, as we finished up the first measurement period.
Workplaces and stress related to them are a top 5 causes of death in the U.S.; dividends have caused zero fatalities. We look at how dividends can provide for you and your loved ones, without trading your health for wealth. True wealth is one that is recurring, even if you're not working.
When it comes to investing, there are two critical “bedrocks” we need to keep in mind. Everything else builds out from there.
Just a week ago, I wrote to you about the dangers of investing in a tired investor go-to called the 60/40 portfolio.
Q32 Bio's Bempikibart and ADX-097 are in Phase 2 trials, targeting autoimmune and inflammatory diseases, with significant potential to address unmet medical needs. The company's unique approach of localized inhibition minimizes side effects and enhances efficacy, differentiating it in the biotech sector. Despite a short cash runway, Q32 Bio's recent merger, strategic reacquisition, and $42 million private placement bolstered its financial position.
Every month, I add or initiate new positions in my closed-end fund portfolio. This creates a snowball of growing monthly cash flow over time. With the market continuing to perform well at/near all-time highs, letting some cash build up also doesn't hurt.
We're a little more than halfway through the year now, so it's a great time to check the state of play on our favorite high-yield plays: 8%+ paying closed-end funds (CEFs).